money_istock-504240346_jansucko
jansucko / iStockphoto.com
28 September 2018

CRISPR specialist raises $80m in funding

US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
20 March 2017   Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Europe
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Biotechnology
23 November 2018   The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.

More on this story

Americas
20 March 2017   Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Biotechnology
23 November 2018   The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Europe
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.

More on this story

Americas
20 March 2017   Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Biotechnology
23 November 2018   The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Europe
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.